Pancuronium
- Atc Codes:M03AC01
- CAS Codes:15500-66-0
- PHARMGKB ID:15500-66-0
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Bulgaria: Pavulon; Cyprus: Pavulon; Czech Republic: Pavulon; Estonia: Pavulon; Finland: Pavulon; France: Pavulon; Germany: Pancuronium; Greece: Pancuronium, Pavulon; Italy: Pavulon; Luxembourg: Pavulon; Netherlands: Pavulon; Poland: Pancuromium; Romania: Pancuronium, Pavulon; Sweden: Pavulon; UK: Pancuronium.
North America
Canada: Pancuronium; USA: Pancuronium.
Latin America
Argentina: Bemicín, Pancurón, Pancuronio, Plumger; Brazil: Pancuron, Pavulon; Mexico: Bromurex, Pancuronio, Panlem.
Asia
Japan: Mioblock.
Drug combinations
Chemistry
Pancuronium Bromide: C~35~H~60~Br~2~N~2~O~4~. Mw: 732.67. (1) Piperidinium, 1,1′-[(2β,3α,5α,16β,17β)-3,17-bis(acetyloxy)androstane-2,16-diyl]bis[1-methyl]-, dibromide; (2) 1,1′-(3α,17β-Dihydroxy-5α-androstan-2β,16β-ylene)bis[1-methylpiperidinium] dibromide diacetate; (3) 2β,16β-Dipiperidino-5α-androstane-3α,17 β – diol diacetate dimethobromide. CAS-15500-66-0 (1971).
Pharmacologic Category
Neuromuscular Blocking Agents, Nondepolarizing. (ATC-Code: M03AC01).
Mechanism of action
Blocks neural transmission at myoneural junction by binding with cholinergic receptor sites.
Therapeutic use
Adjunct to general anesthesia to facilitate endotracheal intubation and relax skeletal muscles during surgery. To facilitate mechanical ventilation in intensive care unit.
Pregnancy and lactiation implications
Unlabeled use
Contraindications
Hypersensitivity to pancuronium, bromide, or any component of the formulation.
Warnings and precautions
Cross-sensitivity with other neuromuscular-blocking agents may occur (use extreme caution in previous anaphylactic reactions). Resistance may occur in burn patients (>30% of body) for period of 5-70 days postinjury. Alkalosis, hypercalcemia, demyelinating lesions, peripheral neuropathies, denervation, infection, muscle trauma, and diabetes mellitus may result in antagonism of neuromuscular blockade. Electrolyte abnormalities, severe hyponatremia, severe hypocalcemia, severe hypokalemia, hypermagnesemia, neuromuscular diseases, acidosis, acute intermittent porphyria, Eaton-Lambert syndrome, myasthenia gravis, renal failure, and hepatic failure may result in potentiation of neuromuscular blockade. Use with caution in hepatic or renal impairment, and in the elderly. Resistance may occur in immobilized patients.